RxDoctor Payments Data

Luis Silva, MD

Internal Medicine · San Antonio, TXNPI 1437169125

Payments from drug & device makers

$349in general payments, 2019–2025

Across 6 payments — averaging $58.23 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Medtronic$152
  • Inari Medical, Inc.$132
  • Otsuka America Pharmaceutical, Inc.$20
  • Johnson & Johnson$18
  • Sunovion Pharmaceuticals Inc.$15
  • Lilly USA, LLC$12

What the payments were for

  • Food & beverage$349100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
21
23
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$349 in reported general payments places this provider in the 50th percentile of 7,675 internal medicine providers in Texas.

See all internal medicine providers in Texas

Medicare billing

Part B allowed, 2024
$123,580
Medicare patients
416
Services billed
1,101

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban453$136,051
XareltoRivaroxaban146$40,879
MyrbetriqMirabegron144$33,644
SantylCollagenase Clostridium Hist.32$21,552
JardianceEmpagliflozin61$18,579
TradjentaLinagliptin68$17,882
FarxigaDapagliflozin Propanediol50$14,455
JanuviaSitagliptin Phosphate50$14,289
Basaglar Kwikpen U-100Insulin Glargine,hum.Rec.Anlog56$13,895
Daptomycin15$11,423
Trelegy ElliptaFluticasone/Umeclidin/Vilanter19$11,353
Potassium Chloride234$10,682
LinzessLinaclotide24$10,500
Atorvastatin Calcium564$8,551
Memantine Hcl203$8,345

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Johnson & JohnsonXarelto$18$40,879146 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 50th percentile of 7,675 internal medicine providers in Texas.

Other internal medicine in San Antonio

See the full list for Texas

Where these figures come from

Is this you, or does something look wrong? →